Biotech startups move first human dosing to Australia for faster cheaper trials

First human doses are getting moved offshore, not just the lab work. Australia is pulling in early biotech trials because startups can clear ethics and regulators faster and start dosing sooner, with less cost drag than the US. That's a direct response to Eroom's law: AI helps discovery, but safety still needs real humans. One comparison puts Phase I at ~$300M in the US vs ~$20M in India, with Australia emerging as a middle path plus lighter trial setup.